EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis

Eleni Christoforidou iD, Emily McFagan, Martha McLaughlin iD, Majid Hafezparast iD

Biochemical Society Transactions · 29.07.2026 · 54 (7) · 901-913

DOI: 10.1042/bst20260896 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, online erschienen am 01.07.2026. Verfasst von Eleni Christoforidou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, School of Life Sciences, University of Sussex, Brighton, U.K. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, DNA-Binding Proteins, TDP-43 Proteinopathies. Die Arbeit nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Motor Neurone Disease Association (MNDA), LifeArc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyotrophic lateral sclerosis (ALS) is the most common form of adult-onset motor neuron disease, characterised by the degeneration of upper and lower motor neurons. The cytoplasmic aggregation of TDP-43 (TAR DNA-binding protein 43), an RNA-binding protein, is considered a hallmark of ALS pathology, found in nearly all postmortem cases of ALS. TDP-43 is normally primarily nuclear, where it has a widespread role in gene regulation. Mutations, extrinsic stressors, and alterations in RNA homeostasis in ALS lead to nuclear depletion of TDP-43 and the formation of cytosolic TDP-43 aggregates. This causes multiple downstream effects on neuronal function and degeneration as well as gene expression. TDP-43 is a promising target as a biomarker, as it is found to be elevated in the biofluids of ALS patients, and its cytoplasmic aggregation can also be observed in peripheral tissues; however, methodological variability and technical limitations currently preclude the establishment of TDP-43 as a standalone biomarker. There are also promising therapeutic strategies in development targeting TDP-43 pathology, but a critical challenge that remains is achieving a balance between eliminating toxic aggregates and preserving the essential functions of TDP-43. In summary, with further research, considering TDP-43 pathology in ALS gives hope for finding future novel diagnostics and therapeutics for ALS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisDNA-Binding ProteinsTDP-43 ProteinopathiesHumansBiomarkersAnimals

Stichwörter der Autor:innen

ALSAmyotrophic Lateral SclerosisMNDMotor Neuron DiseaseTARDBPTDP-43

Substanzen

BiomarkersDNA-Binding ProteinsTARDBP protein, human

Autor:innen und Institutionen

  • Department of Neuroscience, School of Life Sciences, University of Sussex, Brighton, U.K.

ORCID-Profile: Eleni Christoforidou, Martha McLaughlin, Majid Hafezparast

Förderung

  • Motor Neurone Disease Association (MNDA)
  • LifeArc

Zitieren

APA

Christoforidou, E., McFagan, E., McLaughlin, M., & Hafezparast, M. (2026). TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis. Biochemical Society Transactions, 54(7), 901-913. https://doi.org/10.1042/bst20260896

Vancouver

Christoforidou E, McFagan E, McLaughlin M, Hafezparast M. TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis. Biochemical Society Transactions. 2026;54(7):901-913. doi:10.1042/bst20260896

BibTeX
@article{Christoforidou2026,
  author = {Christoforidou, Eleni and McFagan, Emily and McLaughlin, Martha and Hafezparast, Majid},
  title = {TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis},
  journal = {Biochemical Society Transactions},
  year = {2026},
  volume = {54},
  number = {7},
  pages = {901--913},
  doi = {10.1042/bst20260896}
}
Kostenlos starten →